Last reviewed · How we verify

Samia Hassan El-Shishtawy — Portfolio Competitive Intelligence Brief

Samia Hassan El-Shishtawy pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Astrazenica vaccine Astrazenica vaccine phase 3 Viral vector vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Aeras · 1 shared drug class
  2. Bharat Biotech International Limited · 1 shared drug class
  3. CanSino Biologics Inc. · 1 shared drug class
  4. Cellid Co., Ltd. · 1 shared drug class
  5. Crucell Holland BV · 1 shared drug class
  6. D'Or Institute for Research and Education · 1 shared drug class
  7. EuBiologics Co.,Ltd · 1 shared drug class
  8. Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Samia Hassan El-Shishtawy:

Cite this brief

Drug Landscape (2026). Samia Hassan El-Shishtawy — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/samia-hassan-el-shishtawy. Accessed 2026-05-17.

Related